The store will not work correctly when cookies are disabled.
N-(1,3-dimethyl-1H-pyrazol-5-yl)-5-(3-(methylsulfonyl)phenyl)thieno[2,3-d]pyrimidin-4-amine
ID: ALA3730934
PubChem CID: 66835817
Max Phase: Preclinical
Molecular Formula: C18H17N5O2S2
Molecular Weight: 399.50
Molecule Type: Small molecule
This compound is available for customization.
Associated Items:
Names and Identifiers
Canonical SMILES: Cc1cc(Nc2ncnc3scc(-c4cccc(S(C)(=O)=O)c4)c23)n(C)n1
Standard InChI: InChI=1S/C18H17N5O2S2/c1-11-7-15(23(2)22-11)21-17-16-14(9-26-18(16)20-10-19-17)12-5-4-6-13(8-12)27(3,24)25/h4-10H,1-3H3,(H,19,20,21)
Standard InChI Key: LBBYRBJOFMSQCF-UHFFFAOYSA-N
Molfile:
RDKit 2D
27 30 0 0 0 0 0 0 0 0999 V2000
-0.3026 6.2126 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
0.8855 6.3807 0.0000 S 0 0 0 0 0 0 0 0 0 0 0 0
1.3336 7.4939 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
-2.3155 0.7475 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-2.3155 -0.7475 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.0028 -1.5132 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-1.0028 1.5132 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.2917 0.7475 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.2917 -0.7475 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.7138 -1.2033 0.0000 S 0 0 0 0 0 0 0 0 0 0 0 0
2.5889 0.0182 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.7138 1.2033 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.1749 2.6315 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.2517 3.8078 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.8114 5.1995 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.2965 5.4106 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
4.2218 4.2301 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.6621 2.8384 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.9971 3.0138 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-2.2935 3.7700 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-2.4279 5.2511 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-3.8944 5.5664 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-4.6474 4.2692 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-3.6464 3.1521 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.1457 7.3255 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.5295 6.0466 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-5.8412 4.1465 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2 1 2 0
3 2 2 0
4 5 2 0
5 6 1 0
6 9 2 0
8 7 2 0
7 4 1 0
8 9 1 0
9 10 1 0
10 11 1 0
11 12 2 0
12 8 1 0
13 14 2 0
14 15 1 0
15 16 2 0
16 17 1 0
17 18 2 0
18 13 1 0
12 13 1 0
7 19 1 0
19 20 1 0
20 21 1 0
21 22 1 0
22 23 2 0
23 24 1 0
24 20 2 0
15 2 1 0
2 25 1 0
21 26 1 0
23 27 1 0
M END
Associated Targets(Human)
Molecule Features
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
Drug Indications
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanisms of Action
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Calculated Properties
Molecular Weight: 399.50 | Molecular Weight (Monoisotopic): 399.0824 | AlogP: 3.55 | #Rotatable Bonds: 4 |
Polar Surface Area: 89.77 | Molecular Species: NEUTRAL | HBA: 8 | HBD: 1 |
#RO5 Violations: ┄ | HBA (Lipinski): 7 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): ┄ |
CX Acidic pKa: ┄ | CX Basic pKa: 4.06 | CX LogP: 2.46 | CX LogD: 2.46 |
Aromatic Rings: 4 | Heavy Atoms: 27 | QED Weighted: 0.56 | Np Likeness Score: -2.38 |
References
1. (2012) Compounds, pharmaceutical compositions, and methods of treating or preventing neurodegenerative diseases or disorders, |
2. Klaeger, Susan S and 47 more authors. 2017-12-01 The target landscape of clinical kinase drugs. [PMID:29191878] |